The anticancer thiosemicarbazone triapine exerts immune-enhancing activities via immunogenic cell death induction and FAS upregulation

The anticancer thiosemicarbazone triapine exerts immune-enhancing activities via immunogenic cell death induction and FAS upregulation

Abstract The anticancer thiosemicarbazone Triapine is currently in a phase III clinical trial in combination with radiation therapy and cisplatin. Noteworthy, while radiotherapy induces an immune-activating cell death, so called immunogenic cell death (ICD), cisplatin possesses immunomodulatory and...

Full description

Saved in:
Bibliographic Details
Main Authors: Bianca Stiller, Alessia Stefanelli, Hemma Schueffl, Marlene Mathuber, Nadiya Skorokhyd, Judith Gufler, Christine Pirker, Martin Holcmann, Rostyslav Panchuk, Maria Sibilia, Doris Marko, Walter Berger, Christian R. Kowol, Sonja Hager, Petra Heffeter
Format: Article
Language:English
Published: BMC 2025-08-01
Series:Experimental Hematology & Oncology
Subjects:
Anticancer therapy
Thiosemicarbazones
Triapine
Immunogenic cell death
Immunomodulation
Adaptive immune system
Online Access:https://doi.org/10.1186/s40164-025-00700-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40164-025-00700-0

Similar Items